Ziegelbauer K
Bayer AG, Institut für Antiinfektiva Forschung, Wuppertal, Germany.
Antimicrob Agents Chemother. 1998 Jul;42(7):1581-6. doi: 10.1128/AAC.42.7.1581.
BAY 10-8888, a cyclic beta-amino acid, exerts its antifungal activity by inhibition of isoleucyl-tRNA synthetase activity after accumulation to a millimolar concentration inside the cell. We have selected and characterized BAY 10-8888-resistant Candida albicans mutants. Reduced BAY 10-8888 accumulation as well as increased isoleucyl-tRNA synthetase activity was observed in these mutants. Some of the mutants were cross-resistant to cispentacin, a structurally related beta-amino acid, while sensitivities to 5-fluorocytosine and fluconazole remained unchanged in all mutants. All except two in vitro-resistant mutants were pathogenic in a murine candidiasis model, and BAY 10-8888 failed to cure the infection. Furthermore, we have characterized BAY 10-8888 transport and isoleucyl-tRNA synthetase activity in several Candida tropicalis strains which showed MICs higher than those of other Candida strains. An analysis of the C. tropicalis strains revealed that intracellular concentrations of BAY 10-8888 were in the millimolar range, comparable to those for C. albicans. However, these isolates expressed isoleucyl-tRNA synthetase activities about fourfold higher than those for C. albicans. To test the possibility of resistance modeling, we determined the correlations between the intracellular concentration of BAY 10-8888, the specific activity of isoleucyl-tRNA synthetase, the number of free, i.e., noninhibited, isoleucyl-tRNA synthetase molecules/cell, and growth, assuming a linear relation. We found significant correlations between growth and the intracellular concentration of BAY 10-8888 and between growth and the number of free isoleucyl-tRNA synthetase molecules/cell, but not between growth and the specific activity of isoleucyl-tRNA synthetase.
BAY 10 - 8888是一种环状β - 氨基酸,在细胞内积累至毫摩尔浓度后,通过抑制异亮氨酰 - tRNA合成酶的活性发挥其抗真菌活性。我们已筛选并鉴定了对BAY 10 - 8888耐药的白色念珠菌突变体。在这些突变体中观察到BAY 10 - 8888积累减少以及异亮氨酰 - tRNA合成酶活性增加。一些突变体对结构相关的β - 氨基酸顺阿糖胞苷具有交叉耐药性,而所有突变体对5 - 氟胞嘧啶和氟康唑的敏感性保持不变。除两个体外耐药突变体之外,所有突变体在小鼠念珠菌病模型中均具有致病性,并且BAY 10 - 8888无法治愈感染。此外,我们已对几种热带念珠菌菌株中的BAY 10 - 8888转运和异亮氨酰 - tRNA合成酶活性进行了鉴定,这些菌株的最低抑菌浓度高于其他念珠菌菌株。对热带念珠菌菌株的分析表明,BAY 10 - 8888的细胞内浓度处于毫摩尔范围内,与白色念珠菌的浓度相当。然而,这些分离株表达的异亮氨酰 - tRNA合成酶活性比白色念珠菌高约四倍。为了测试耐药建模的可能性,我们假设存在线性关系,确定了BAY 10 - 8888的细胞内浓度、异亮氨酰 - tRNA合成酶的比活性、游离(即未受抑制)的异亮氨酰 - tRNA合成酶分子/细胞数量与生长之间的相关性。我们发现生长与BAY 10 - 8888的细胞内浓度之间以及生长与游离异亮氨酰 - tRNA合成酶分子/细胞数量之间存在显著相关性,但生长与异亮氨酰 - tRNA合成酶的比活性之间不存在显著相关性。